Last week the National Institute for Health and Care Excellence (NICE) decided not to recommend Xalkori for the treatment of ROS-positive non-small cell lung cancer in the United Kingdom. More information here:
NICE Appraisal Consultation Document
NICE shoots down Pfizer’s Xalkori in ROS1-positive patients, inviting a CDF proposal instead (from Fierce Biotech)
I saw that.
Perhaps a letter from 200 ROS 1ders to them is in order!!!!!
Xo
Bonnie Addario / Lung Cancer Survivor & Chair bonnie@lungcancerfoundation.org / 650-598-2857
Bonnie J. Addario Lung Cancer Foundation (ALCF) 1100 Industrial Road, Suite 1 San Carlos, CA 94070 http://www.lungcancerfoundation.org
>